• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
AR3
Click for more information
0.00% 14.5¢

AUSTRALIAN RARE EARTHS LIMITED - Corporate Spotlight

Market Cap $22.90M  ! watchlist Created with Sketch. Add to my watchlist
Metals & Mining Industrial Metals & Minerals

Australian Rare Earths Limited is an Australia-based mineral exploration and development... Australian Rare Earths Limited is an Australia-based mineral exploration and development company, which is focused on ionic clay hosted rare earths resource opportunities in South Australia and Victoria. The Company is engaged in the exploration and development of its flagship Koppamurra Project. It owns 100% of Koppamurra Project, which is located in South Australia and Victoria. The Company holds six exploration licenses (ELs), four covering the area between Comaum and Keith in South Australia and two cover the area between Apsley and Minimay in Western Victoria, Australia. The Company has granted South Australian EL’s 6509, EL6613, EL6690 and EL6691 and Victorian EL007254 and EL7719.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

No Corporate Spotlight currently available.

(20min delay)
Last
14.5¢ 		Change
0.000(0.00%) 		Mkt cap ! $22.90M
Open High Low Value Volume
14.5¢ 14.5¢ 14.5¢ $13.15K 90.74K

Buyers (Bids)

No. Vol. Price($)
3 11632 14.5¢
 

Sellers (Offers)

Price($) Vol. No.
15.0¢ 125000 2
View Market Depth
Last trade - 09.59am 02/10/2024 (20 minute delay) ?
AR3 (ASX) Chart

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
Firebird achieves preliminary approvals for its Jinshi plant design Firebird Metals Ltd has reached a significant stage in development of its battery-grade manganese sulphate plant in China
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Canada orders national security review over CGN's 11.26% opposition to Paladin-Fission deal Paladin has disclosed its attempted takeover of Fission Uranium Corp was blocked by a Chinese shareholder late last month.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.